drugset
drugset / Trial / NCT04495322

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

NCT04495322 ↗

Phase 1 Completed 66 enrolled TaiGen Biotechnology Co., Ltd. R&G Pharma Studies Co.,Ltd. · collab
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics profiles of TG-1000 in healthy volunteers, and to evaluate the food effect on pharmacokinetics of single oral dose of TG-1000 in healthy volunteers.

Timeline

Start
2020-07-17
Primary completion
2020-11-26
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TG-1000 Unknown 10 mg Oral
Subject TG-1000 Unknown 20 mg Oral
Subject TG-1000 Unknown 40 mg Oral
Subject TG-1000 Unknown 80 mg Oral
Subject TG-1000 Unknown 120 mg Oral
Subject TG-1000 Unknown 160 mg Oral

Indications

No indication recorded.